The prevalence of diabetes mellitus has increased in recent decades, with approximately 90% of diabetic patients currently worldwide classified as type 2 diabetes mellitus (DM2). In 2030, WHO projects 366 million adults will have DM2 worldwide.
Although not all patients were properly treated, the ones prescribed medication have very unsatisfactory adherence rates, potentially impairing DM2 treatment and increasing the burden of disease.
Considering public health implications of diabetes, awareness, education programs, and pharmaceutical care for DM2 patients may improve adherence to treatment. DM2 may be underdiagnosed due to the diminished access to physicians in certain regions of the country.
The data are cross-sectional in nature and do not allow for conclusive causal interpretations.
LIMITATIONS
The projected DM2 prevalence of 4% is lower than predicted values of 10.3% obtained from the International Diabetes Federation (IDF), possibly due to reduced patient awareness.
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In addition, IDF estimates may be uncertain since epidemiological data are very scarce in Brazil, and the published studies present several limitations (outdated or representative of only some cities). 1, 6 The present study corroborates a previous national survey, conducted by the Ministry of Health, reporting 5.3% prevalence with similar intra-country variations.
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Although most Brazilian DM2 respondents are currently taking prescription drugs, few are adherent to their medication or have adequate knowledge about their symptoms.
Proportions of adherent DM2 patients and controlled glycemia were similar to those demonstrated in previous studies in Brazil. 
Characteristics & Complications
Note: Adherence was only asked of those who reported taking a prescription medication for DM2 (diagnosed N=842; projected N=4,823,357) The majority of those with DM2 were taking a prescription medication (86.4%).
Less than half of these were perfectly adherent to their medication (Figure 4 ). 
RESULTS
Projected estimates reveal that 4.0% (n=5,585,272) of the Brazilian adult population has a DM2 diagnosis.
Further broken down by region, projected estimates reveal the highest prevalence of DM2 in the Central-West and Southeast at 4.5% with the North at 1.7% (Figure 1 ).
Prevalence
The majority of respondents did not know their HbA1c levels (90.6%) and only 4% had levels that were considered controlled (HbA1c<7; Figure 2 ).
Most respondents had not experienced recent hypoglycemia (69.6%; Figure 3 ).
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Control
Of those diagnosed, average age was 56.5 years old, 53.2% were female, 54.3% were white, 80.9% had less than a degree, 69.3% made less than R$ 6,500 annually, 68.4% had public insurance, and 73.5% were overweight or obese ( Table 1 ).
•
Demographics & Health Characteristics
On average, respondents had been diagnosed with DM2 for about 8.6 years.
The least common complication was diabetes with end organ damage (3.2%) and the most common was kidney disease (4.9%; Table 2 ).
• Respondents of the NHWS are recruited from an Internet panel using a random stratified sampling framework to ensure the demographic composition (with respect to age and gender) is representative of the adult Brazilian population based on data from International Data Base of the U.S. Census Bureau and Organization for Economic Cooperation and Development.
Of the 24,000 total NHWS respondents, 1,026 reported a D2M diagnosis and were included in the sample.
Weights were calculated to be representative of the Brazilian adult population. Weighting variables consisted of age, gender, and socioeconomic status. Analyses were based on the weighted data.
Means and standard deviations were reported for continuous variables and percentages and weighted counts were reported for categorical variables.
The Morisky Medication Adherence Scale-4 5 was used regarding respondents' diabetes medication to categorize those with no non-adherent behaviors as "adherent." All other respondents were considered "non-adherent." Adherence was only asked of those who reported taking DM2 prescription medications.
Characteristics & Complications:
years diagnosed with DM2 and diabetes-related complications (e.g., neuropathic pain or kidney disease).
Control: examined by HbA1c levels and experience with hypoglycemia in the last three months.
Medication Adherence: respondents were asked if they were currently taking prescription medication (medication status) for their DM2. 
